by Emily Burke, PhD | Apr 24, 2019 | Front Page Feature
Coming Soon? A New Biologic For the past two decades, monoclonal antibodies (mAbs) have dominated the biologic drugs market. Doctors use these blockbuster products for a range of diseases, including many cancers and autoimmune diseases. In addition to their... 
by Emily Burke, PhD | Apr 17, 2019 | Front Page Feature
A Bone To Pick With Osteoporosis Last week, the FDA approved Evenity, Amgen’s (Thousand Oaks, CA) new osteoporosis drug. Heralded as effective at rebuilding bone, the drug promises to be an important weapon in the fight against osteoporosis. Osteoporosis is the loss... 
by Emily Burke, PhD | Apr 9, 2019 | Biology Basics
Down the Hatch! Then What? When popping a pill, how often do we think about what happens next—to the pill, or to our bodies? Maybe we assume the body welcomes any extra help to soothe our headache or control our blood pressure. This WEEKLY looks into the mystery of... 
by Emily Burke, PhD | Apr 3, 2019 | Oncology
On A Tumor’s Turf Solid tumors are generally considered more difficult to treat than blood cancers. For example, chimeric antigen receptor T-cell (CAR-T) therapy has been amazingly effective against blood cancers that failed to respond to other types of... 
by Emily Burke, PhD | Mar 26, 2019 | Neuroscience
Multiple SCLEROSIS Awareness March is Multiple Sclerosis (MS) Awareness Month, so this WEEKLY takes a look at the science behind the disease and some of the treatments developed for it. MS typically occurs in susceptible individuals between the ages of 20 and 50, and... 
